Chapter 16: Antiinflammatory, Antiarthritis & Related Agents

Antiinflammatory, Antiarthritis & Related Agents nursing pharmacology chapter, "Antiinflammatory, Antiarthritis, and Related Agents," provides a detailed overview of pharmacological interventions used to manage the inflammatory response, which is the body’s nonspecific reaction to cell injury resulting in characteristic signs like pain, swelling, heat, and redness. The chapter examines several critical drug classes known for their analgesic (pain-blocking), antiinflammatory, and antipyretic (fever-blocking) properties. Salicylates, including aspirin, represent some of the oldest agents used for these purposes, acting primarily by inhibiting the synthesis of prostaglandins, key mediators of inflammation and fever. Prolonged or high-level salicylate use can lead to serious adverse effects, including salicylism. Nonsteroidal Antiinflammatory Drugs (NSAIDs) are widely prescribed and function by blocking both the COX-1 enzyme, which is involved in protective functions like maintaining the stomach lining and renal water balance, and the COX-2 enzyme, which mediates inflammation at injury sites. Blocking COX-1 is responsible for the associated GI irritation, bleeding risks, and cardiovascular (CV) complications, which are highlighted by black box warnings associated with this drug class. A related agent, acetaminophen, is frequently used to treat pain and fever by acting directly on the hypothalamus to induce vasodilation and sweating, but unlike salicylates and NSAIDs, it does not provide antiinflammatory effects and carries a major risk of potentially fatal hepatotoxicity if overdosed. For chronic inflammatory diseases like rheumatoid arthritis, specialized Antiarthritis Agents are utilized. Chrysotherapy, involving gold salts like auranofin, is a highly toxic treatment reserved for patients unresponsive to conventional therapy, operating by inhibiting macrophage phagocytosis and decreasing the release of tissue-destroying lysosomal enzymes. The chapter also extensively covers Disease-Modifying Antirheumatic Drugs (DMARDs), such as Tumor Necrosis Factor (TNF) blockers (like etanercept and adalimumab) and other agents (like leflunomide and anakinra), which are selected early in the disease course to aggressively alter the inflammatory process and slow joint damage. Because TNF blockers significantly suppress the body’s immune and inflammatory response, they carry severe risks, including serious infections and cancer development, necessitating careful patient screening and monitoring. Throughout these discussions, comprehensive nursing considerations are outlined, emphasizing proper dosage, assessment for specific contraindications (e.g., Reye syndrome risk with aspirin in children with viral infections, allergies to sulfonamides with celecoxib, or active infection with DMARDs), cultural variations in drug sensitivity, and thorough patient education regarding the avoidance of multiple over-the-counter (OTC) products to prevent accidental toxicity.